BPG is committed to discovery and dissemination of knowledge
Featured Articles
11/19/2020 3:26:25 AM | Browse: 12 | Download: 11
Publication Name World Journal of Clinical Oncology
Manuscript ID 59442
Country/Territory United States
2020-09-11 16:01
Peer-Review Started
2020-09-11 16:02
To Make the First Decision
Return for Revision
2020-09-24 16:31
2020-10-08 04:19
Second Decision
2020-10-20 12:32
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2020-10-20 21:20
Articles in Press
2020-10-20 21:20
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2020-11-08 14:46
Publish the Manuscript Online
2020-11-18 14:20
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Frontier
Article Title Tumor-specific lytic path “hyperploid progression mediated death”: Resolving side effects through targeting retinoblastoma or p53 mutant
Manuscript Source Invited Manuscript
All Author List Frank-Un Hong, Miguel Castro and Klaus Linse
Funding Agency and Grant Number
Corresponding author Frank-Un Hong, PhD, Research Scientist, Department of Research and Development, Bio-Synthesis, 612 E. Main St., Lewisville, TX 75057, United States. fhong@coh.org
Key Words Retinoblastoma protein; P53 protein; Cancer; Checkpoint; Taxol; Tumor-specific lytic path
Core Tip Side effect remains a major impediment to achieving a cure. An important advance has been made to establish the principle of cytotoxic cancer therapy at the mechanistic level. It concerns the discovery of the tumor-specific lytic path “hyperploid progression mediated death” targeting retinoblastoma (or p53) mutants defective in G1 DNA damage checkpoint. By triggering the lytic path, tumor specificity can be achieved at the genetic level for cytotoxic drugs.
Publish Date 2020-11-18 14:20
Citation Hong F, Castro M, Linse K. Tumor-specific lytic path “hyperploid progression mediated death”: Resolving side effects through targeting retinoblastoma or p53 mutant. World J Clin Oncol 2020; 11(11): 854-867
Url https://www.wjgnet.com/2218-4333/full/v11/i11/854.htm
DOI https://dx.doi.org/10.5306/wjco.v11.i11.854
Full Article (PDF) WJCO-11-854.pdf
Full Article (Word) WJCO-11-854.docx
Manuscript File 59442_Auto_Edited.docx
Answering Reviewers 59442-Answering reviewers.pdf
Audio Core Tip 59442-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 59442-Conflict-of-interest statement.pdf
Copyright License Agreement 59442-Copyright license agreement.pdf
Peer-review Report 59442-Peer-review(s).pdf
Scientific Misconduct Check 59442-Scientific misconduct check.pdf
Scientific Editor Work List 59442-Scientific editor work list.pdf